Variant Annotation ID	Variant/Haplotypes	Gene	Drug(s)	PMID	Phenotype Category	Significance	Notes	Sentence	Alleles	Specialty Population	Metabolizer types	isPlural	Is/Is Not associated	Direction of effect	PD/PK terms	Multiple drugs And/or	Population types	Population Phenotypes or diseases	Multiple phenotypes or diseases And/or	Comparison Allele(s) or Genotype(s)	Comparison Metabolizer types
1451834452	CYP3A4*1, CYP3A4*17	CYP3A4	nifedipine	15634941	Other, Metabolism/PK	not stated	in vitro expression of the recombinant CYP3A4*17 allelic protein and the wild-type protein	CYP3A4 *17 is associated with decreased metabolism of nifedipine as compared to CYP3A4 *1.	*17			Is	Associated with	decreased	metabolism of					*1	
1451159680	rs5031016	CYP2A6	warfarin	22248286	Dosage	no	No association was found between this variant and warfarin-maintenance dose. Described as CYP2A6*7 in this study.	Allele G is not associated with increased dose of warfarin in people with an international normalized ratio (INR) of 2.0-3.0 as compared to allele A.	G			Is	Not associated with	increased	dose of		in people with	Other:an international normalized ratio (INR) of 2.0-3.0		A	
1183684657	CYP2D6 ultrarapid metabolizer genotype	CYP2D6	tramadol	18204346	Metabolism/PK	yes	Median (+)R,R-tramadol area under the curve was 2386 +/- 681 mg.h.L in PMs and 667 +/- 243 mg.h.L in UMs.  Median (-)S,S-tramadol area under the curve was 2370 +/- 631 mg.h.L in PMs and 561 +/- 193 mg.h.L in UMs.The UM group consisted of subjects with one active duplication allele (*1x2,*2x2,*35x2,*41x2) and one active allele (*1,*2,*9,*10,*35,*41). The PM group consisted of subjects with both alleles from the group *3,*4,*5,*6.	CYP2D6 ultra-metabolizer genotype is associated with increased metabolism of tramadol in healthy individuals as compared to CYP2D6 poor metabolizer genotype.			ultrarapid metabolizer genotype	Is	Associated with	increased	metabolism of		in healthy individuals				poor metabolizer genotype
1451306860	CYP2C9*11	CYP2C9	warfarin	33350885	Dosage	not stated	"""This case suggests that CYP2C9 *11/*11 carriers require approximately two thirds less warfarin than CYP2C9"" normal function homozygotes."	CYP2C9 *11/*11 is associated with decreased dose of warfarin.	*11/*11			Is	Associated with	decreased	dose of						
1448997750	CYP2B6*1, CYP2B6*18	CYP2B6	efavirenz	16495778	Metabolism/PK	yes	Please note that in the paper the allele was referred to as CYP2B6*16. CYP2B6*16 and *18 alleles have been consolidated by PharmVar in Jan 2020, with *16 now listed as a suballele of *18 (CYP2B6*18.002). This annotation is updated to be on CYP2B6*18, instead of CYP2B6*16.	CYP2B6 *1/*18 is associated with increased concentrations of efavirenz in people with HIV Infections as compared to CYP2B6 *1/*1.	*1/*18			Is	Associated with	increased	concentrations of		in people with	Disease:HIV Infections		*1/*1	
1448631821	CYP2C19*1, CYP2C19*2	CYP2C19	clomipramine, desmethyl clomipramine	28470111	Metabolism/PK	no	in a single individual	CYP2C19 *1/*2 is associated with increased trough concentration of clomipramine and desmethyl clomipramine.	*1/*2			Is	Associated with	increased	trough concentration of	and					
1451159740	rs371194629	HLA-G	methotrexate	19088262		no	"Patients were defined as responders based on a 28-joint Disease Activity Score (DAS28) of less than 3.2, or non-responders if DAS28 was greater than 3.2. Variant described as ""HLA-G -/- 14 bp polymorphism""."	Genotype del/del is not associated with increased response to methotrexate in people with Arthritis, Rheumatoid.	del/del			Is	Not associated with	increased	response to		in people with	Other:Arthritis, Rheumatoid			
1183684661	CYP2D6 normal metabolizer genotype	CYP2D6	tramadol	18204346	Metabolism/PK	yes	Median (+)R,R-tramadol area under the curve was 2386 +/- 681 mg.h.L in PMs and 790 +/- 296 mg.h.L in UMs.  Median (-)S,S-tramadol area under the curve was 2370 +/- 631 mg.h.L in PMs and 663 +/- 229 mg.h.L in UMs. The EM group contained subjects with 2 active alleles (*1,*2,*9,*10,*35,*41). The PM group consisted of subjects with both alleles from the group *3,*4,*5,*6.	CYP2D6 normal metabolizer genotype is associated with increased metabolism of tramadol in healthy individuals as compared to CYP2D6 poor metabolizer genotype.			normal metabolizer genotype	Is	Associated with	increased	metabolism of		in healthy individuals				poor metabolizer genotype
982047744	CYP2D6*1xN	CYP2D6	codeine	19692698	Metabolism/PK	not stated	A 2 year old boy with an ultrarapid-metabolizer CYP2D6 phenotype who had undergone elective adenotonsillectomy was sent home with codeine. Two days later was found unresponsive with absent vital signs and a supratherapeutic morphine thought to be due to an increased conversion of codeine to morphine.	CYP2D6 *1xN is associated with increased metabolism of codeine.	*1xN			Is	Associated with	increased	metabolism of						
1451152848	CYP2D6 poor metabolizer phenotype	CYP2D6	codeine	9357098	Metabolism/PK	not stated	Healthy volunteers were previously phenotyped using debrisoquine. A negative correlation between debrisoquine metabolic ratio and levels of O-demethylated codeine metabolites was found.	CYP2D6 poor metabolizer phenotype is associated with decreased metabolism of codeine in healthy individuals as compared to CYP2D6 normal metabolizer phenotype.			poor metabolizer phenotype	Is	Associated with	decreased	metabolism of		in healthy individuals				normal metabolizer phenotype
1449191920	rs113993960	CFTR	ivacaftor / lumacaftor	28325531	Efficacy	yes	Study found a significant improvement in FEV in all patients following 3 months of treatment. There was no difference in patients' BMI.	Genotype del/del is associated with response to ivacaftor / lumacaftor in people with Cystic Fibrosis.	del/del			Is	Associated with		response to		in people with	Disease:Cystic Fibrosis			
1449192330	rs74551128	CFTR	ivacaftor / lumacaftor	27334259	Efficacy	not stated	A455E allele. Rectal organoids carrying the A455E allele showed increased CFTR function as measured by FIS and SLA assay. Authors predict that cystic fibrosis patients carrying the A455E allele would have a clinical response to ivacaftor/lumacaftor treatment.	Allele A is associated with response to ivacaftor / lumacaftor.	A			Is	Associated with		response to						
1183632366	CYP2D6*1, CYP2D6*4	CYP2D6	codeine	19940985	Metabolism/PK	yes	Lower plasma concentrations of the morphine metabolite M3G and undetectable levels of M6G were found in the two poor metabolizers (*4/*4) compared to extensive metabolizers (*1/*1 +*1/*4). PM were determined on the basis of their CYP2D6*3, *4, and *6 alleles.	CYP2D6 *4/*4 is associated with decreased metabolism of codeine in people with Kidney Failure, Chronic as compared to CYP2D6 *1/*1 + *1/*4.	*4/*4			Is	Associated with	decreased	metabolism of		in people with	Disease:Kidney Failure, Chronic		*1/*1 + *1/*4	
982047720	CYP2D6*2, CYP2D6*2xN	CYP2D6	codeine	16920476	Metabolism/PK	not stated	The death of a full-term healthy male infant was attributed to supratherapeutic morphine concentrations via breast milk from his mother, who was taking codeine and found to be an ultra-rapid metabolizer for CYP2D6 (*2A/*2xN) resulting in increased formation of morphine.	CYP2D6 *2/*2xN is associated with increased metabolism of codeine.	*2/*2xN			Is	Associated with	increased	metabolism of						
1449192352	rs113993960	CFTR	ivacaftor / lumacaftor	27334259	Efficacy	not stated	F508del allele. Rectal organoids with the del/del genotype or carrying the del allele and a Class I mutation responded to treatment with ivacaftor and lumacaftor as measured by FIS and SLA assay.	Allele del is associated with response to ivacaftor / lumacaftor.	del			Is	Associated with		response to						
827566506	CYP2D6*2, CYP2D6*2xN, CYP2D6*41	CYP2D6	codeine	16819548	Metabolism/PK	yes	Refers to the CYP2D6 ultra-fast metabolizer (UM) phenotype, with a genotype of *2 x2/ *41. Statistics were carried out on combined UM genotypes. UM individuals were defined as carriers of one gene duplication allele (*1 x2, *2 x2, *35 x2) and one active CYP2D6 gene (*1, *2, *9, *10, *41, *35). Higher plasma levels of morphine, morphine-3-glucuronide and morphine-6-glucuronide were found in UM individuals compared to extensive metabolizers (EM).	CYP2D6 *2xN/*41 (assigned as ultrarapid metabolizer phenotype phenotype) is associated with increased metabolism of codeine in healthy individuals as compared to CYP2D6 normal metabolizer.	*2xN/*41		ultrarapid metabolizer phenotype	Is	Associated with	increased	metabolism of		in healthy individuals				normal metabolizer
1451307925	rs9839376	KCNMB2	ritodrine	32371615	Efficacy	yes	variant-type homozygote carriers of rs9839376  had 2.68 [95% confidence interval (CI), 1.16-6.20] times the hazard of time to delivery compared to wild- type allele carriers.	Genotype CC is associated with decreased response to ritodrine as compared to genotypes CT + TT.	CC			Is	Associated with	decreased	response to					CT + TT	
1451307920	rs7624046	KCNMB2	ritodrine	32371615	Efficacy	yes	variant-type homozygote carriers of rs7624046  had 2.06 [95% confidence interval (CI), 1.14–3.73] times the hazard of time to delivery compared to wild- type allele carriers.	Genotype TT is associated with decreased response to ritodrine as compared to genotypes CC + CT.	TT			Is	Associated with	decreased	response to					CC + CT	
1183960706	rs74503330	CFTR	ivacaftor	22293084	Efficacy	yes	as compared to baseline. In vitro assays using transfected Fisher Rat Thyroid cells expressing CFTR. Before treatment, cells were activated by exposure to PKA and ATP before ivacaftor treatment. Cells expressing S1251N-CFTR (rs74503330 allele A) responded to ivacaftor treatment as measured by a significantly enhanced channel open probability and increased chloride transport. Single channel current amplitude at 80mV was not significantly enhanced.	Allele A is associated with increased response to ivacaftor.	A			Is	Associated with	increased	response to						
1451308040	NAT2 slow acetylator	NAT2	isoniazid	33165168	Metabolism/PK	no	The AUCT were approximately two- and four-fold higher in the PGx- treatment (200 mg) and standard-treatment (300mg) groups, respectively, than that in the reference group (rapid acetylator, 300 mg).	NAT2 slow acetylator is associated with increased concentrations of isoniazid in healthy individuals as compared to NAT2 rapid acetylator.			slow acetylator	Is	Associated with	increased	concentrations of		in healthy individuals				rapid acetylator
1451153620	CYP2D6 poor metabolizer phenotype	CYP2D6	codeine	10850391	Metabolism/PK	not stated	Single subject with CYP2D6 poor metabolizer phenotype was found to have a substantially higher metabolic ratio of codeine compared to normal metabolizers. Subjects were phenotyped using codeine, dextromethorphan and debrisoquine. No genotyping was carried out.	CYP2D6 poor metabolizer phenotype is associated with decreased metabolism of codeine in healthy individuals as compared to CYP2D6 normal metabolizer phenotype.			poor metabolizer phenotype	Is	Associated with	decreased	metabolism of		in healthy individuals				normal metabolizer phenotype
1451308140	NAT2 slow acetylator	NAT2	rifapentine	32815870	Metabolism/PK	not stated	NAT2 slow acetylators had greater week 4 plasma concentrations of rifapentine (P = 2.6 × 10) and 25-desacetyl rifapentine (P = 7.0 × 10) among all participants, and in efavirenz and nevirapine subgroups.	NAT2 slow acetylator is associated with increased concentrations of rifapentine in people with HIV Infections.			slow acetylator	Is	Associated with	increased	concentrations of		in people with	Other:HIV Infections			
1451308160	CYP2B6 poor metabolizer	CYP2B6	efavirenz	32815870	Metabolism/PK	not stated	CYP2B6 poor metabolizers had greater efavirenz concentrations at all weeks.	CYP2B6 poor metabolizer is associated with increased concentrations of efavirenz in people with HIV Infections.			poor metabolizer	Is	Associated with	increased	concentrations of		in people with	Other:HIV Infections			
1451308144	NAT2 slow acetylator	NAT2	efavirenz	32815870	Metabolism/PK	not stated	NAT2 slow acetylators also had greater plasma efavirenz and nevirapine concentration increases from baseline to week 4, and greater decreases from baseline in clearance.	NAT2 slow acetylator is associated with increased concentrations of efavirenz in people with HIV Infections.			slow acetylator	Is	Associated with	increased	concentrations of		in people with	Other:HIV Infections			
1451161780	rs1045642	ABCB1	methadone	21589866	Dosage	no	No significant difference in methadone dose between genotypes. No details about which specific variants/alleles were tested for. Variant referred to as C3435T. Please note that alleles have been complemented to the positive strand.	Allele G is not associated with dose of methadone in people with Opioid-Related Disorders as compared to allele A.	G			Is	Not associated with		dose of		in people with	Other:Opioid-Related Disorders		A	
1451330400	CYP2D6*1, CYP2D6*10	CYP2D6	propafenone	12421483	Metabolism/PK	yes	"""patients with homozygous mutant of CYP2D6*10 ... had a Cmax of propafenone two times as high as those of wild-type genotype"". The *10 allele was detected using a PCR/RFLP method."	CYP2D6 *10/*10 is associated with increased concentrations of propafenone in people with Arrhythmias, Cardiac as compared to CYP2D6 *1/*1.	*10/*10			Is	Associated with	increased	concentrations of		in people with	Disease:Arrhythmias, Cardiac		*1/*1	
1451330363	CYP2D6*1, CYP2D6*10	CYP2D6	propafenone	12421483	Efficacy	yes	"""patients with homozygous mutant of CYP2D6*10 ... showed a two fold higher inhibitory rate of VPC compared with those with homozygous CYP2D6*1"". The *10 allele was detected using a PCR/RFLP method."	CYP2D6 *10/*10 is associated with increased response to propafenone in people with Arrhythmias, Cardiac as compared to CYP2D6 *1/*1.	*10/*10			Is	Associated with	increased	response to		in people with	Disease:Arrhythmias, Cardiac		*1/*1	
1449716734	rs1128503	ABCB1	fentanyl	29601950	Dosage	yes	Please note that alleles have been complemented to the positive strand. (CYP3A5 variants were not genotyped in the study.)	Genotype AA is associated with increased dose of fentanyl in women with Pain, Postoperative as compared to genotypes AG + GG.	AA			Is	Associated with	increased	dose of		in women with	Disease:Pain, Postoperative		AG + GG	
1451308122	NAT2 slow acetylator	NAT2	nevirapine	32815870	Metabolism/PK	not stated	NAT2 slow acetylators also had greater plasma efavirenz and nevirapine concentration increases from baseline to week 4, and greater decreases from baseline in clearance.	NAT2 slow acetylator is associated with increased concentrations of nevirapine in people with HIV Infections.			slow acetylator	Is	Associated with	increased	concentrations of		in people with	Other:HIV Infections			
1451161820	rs1045642	ABCB1	methadone	21589866	Metabolism/PK	no	No significant difference in concentrations of (R)-, (S)- or (R,S)-methadone between genotypes. No details about which specific variants/alleles were tested for. Variant referred to as C3435T. Please note that alleles have been complemented to the positive strand.	Allele G is not associated with concentrations of methadone in people with Opioid-Related Disorders as compared to allele A.	G			Is	Not associated with		concentrations of		in people with	Other:Opioid-Related Disorders		A	
1451153720	CYP2D6*1, CYP2D6*1xN, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6	CYP2D6	(R)-methadone, (S)-methadone	11270921	Metabolism/PK	yes	Concentrations of both enatiomers to dose-to-weight ratios were significantly lower in subjects who were identified as having at least 3 CYP2D6 alleles. Allele multiplication was determined using RFLP. Subjects were also genotyped for the CYP2D6*3, *4, *5, *6 alleles (rsIDs are not provided).	CYP2D6 *1/*1xN is associated with decreased concentrations of (R)-methadone and (S)-methadone in people with Heroin Dependence as compared to CYP2D6 *1/*1 + *1/*3 + *1/*4 + *1/*5 + *1/*6 (assigned as normal metabolizer genotype phenotype) .	*1/*1xN			Is	Associated with	decreased	concentrations of	and	in people with	Other:Heroin Dependence		*1/*1 + *1/*3 + *1/*4 + *1/*5 + *1/*6	normal metabolizer genotype
1451161371	CYP2D6*1, CYP2D6*2, CYP2D6*2xN	CYP2D6	methadone	21589866	Efficacy	yes	CYP2D6 ultrarapid metabolizers were significantly overrepresented in responders compared to non-responders, as defined by drug misuse during methadone maintenance therapy. No details about which specific variants/alleles were tested for.	CYP2D6 *1/*2xN + *2/*2xN are associated with increased response to methadone in people with Opioid-Related Disorders as compared to CYP2D6 *1/*1.	*1/*2xN + *2/*2xN			Are	Associated with	increased	response to		in people with	Other:Opioid-Related Disorders		*1/*1	
1451161472	CYP2D6*1, CYP2D6*2, CYP2D6*2xN	CYP2D6	methadone	21589866	Dosage	yes	CYP2D6 ultrarapid metabolizers had significantly higher doses of methadone compared to those classed as normal metabolizers. No details about which specific variants/alleles were tested for are given and it is not apparent how different genotypes were categorized into metabolizer phenotypes.	CYP2D6 *1/*2xN + *2/*2xN (assigned as ultrarapid metabolizer phenotype) are associated with increased dose of methadone in people with Opioid-Related Disorders as compared to CYP2D6 normal metabolizer genotype.	*1/*2xN + *2/*2xN		ultrarapid metabolizer	Are	Associated with	increased	dose of		in people with	Other:Opioid-Related Disorders			normal metabolizer genotype
1451161540	CYP2D6*1, CYP2D6*2, CYP2D6*2xN	CYP2D6	methadone	21589866	Metabolism/PK	yes	CYP2D6 ultrarapid metabolizers had significantly higher doses of (R)-, (S)- and (R,S)-methadone compared to those classed as normal metabolizers. No details about which specific variants/alleles were tested for are given and it is not apparent how different genotypes were categorized into metabolizer phenotypes.	CYP2D6 *1/*2xN + *2/*2xN (assigned as ultrarapid metabolizer phenotype) are associated with increased concentrations of methadone in people with Opioid-Related Disorders as compared to CYP2D6 normal metabolizer genotype.	*1/*2xN + *2/*2xN		ultrarapid metabolizer	Are	Associated with	increased	concentrations of		in people with	Other:Opioid-Related Disorders			normal metabolizer genotype
1451153754	CYP2D6*1, CYP2D6*1xN, CYP2D6*3, CYP2D6*4, CYP2D6*6	CYP2D6	methadone	11270921	Efficacy	no	A greater proportion of patients identified as poor metabolizers were considered to have successfully followed MMT compared to those identified as ultrarapid metabolizers. However, this was not a significant difference. Patients were genotyped for the CYP2D6*3, *4, *5 and *6 alleles (rsIDs not given), while allele multiplication was assessed using RFLP.	CYP2D6 *1/*1xN is associated with decreased response to methadone in people with Heroin Dependence as compared to CYP2D6 *3/*4 + *4/*4 + *4/*6 (assigned as poor metabolizer genotype phenotype) .	*1/*1xN			Is	Associated with	decreased	response to		in people with	Other:Heroin Dependence		*3/*4 + *4/*4 + *4/*6	poor metabolizer genotype
1451161360	CYP3A5*1, CYP3A5*3	CYP3A5	methadone	21589866	Efficacy	no	No significant difference in genotype or phenotype frequencies between responders and non-responders, as defined by drug misuse during methadone maintenance therapy. No details about which specific variants/alleles were tested for.	CYP3A5 *3/*3 is not associated with response to methadone in people with Opioid-Related Disorders as compared to CYP3A5 *1/*1 + *1/*3.	*3/*3			Is	Not associated with		response to		in people with	Other:Opioid-Related Disorders		*1/*1 + *1/*3	
1451161620	CYP3A5*1, CYP3A5*3	CYP3A5	methadone	21589866	Dosage	no	No significant difference in methadone dose between genotypes. No details about which specific variants/alleles were tested for.	CYP3A5 *3/*3 is not associated with dose of methadone in people with Opioid-Related Disorders as compared to CYP3A5 *1/*1 + *1/*3.	*3/*3			Is	Not associated with		dose of		in people with	Other:Opioid-Related Disorders		*1/*1 + *1/*3	
1451205960	CYP2D6*2	CYP2D6	tramadol	23567787	Efficacy	no	No significant difference in pain intensity scales over the course of tramadol therapy between genotype groups. Patients were only genotyped for the CYP2D6*2 allele.	CYP2D6 *2 is not associated with response to tramadol in people with Neuralgia.	*2			Is	Not associated with		response to		in people with	Other:Neuralgia			
1184989377	CYP2C9*1, CYP2C9*3	CYP2C9	phenytoin	25096692	Dosage	no	In individuals who experienced severe cutaneous adverse reactions (SCARs) when taking phenytoin, the average daily dose of phenytoin was not significantly different between those who carried the CYP2C9*3 allele and those who did not.	CYP2C9 *3 is not associated with dose of phenytoin in people with severe cutaneous adverse reactions as compared to CYP2C9 *1/*1.	*3			Is	Not associated with		dose of		in people with	Disease:severe cutaneous adverse reactions		*1/*1	
1451151724	rs3812718	SCN1A	phenytoin	32457604	Efficacy	no	No significant association between the variant and the number of patients with drug-resistant epilepsy. Please note that alleles have been complemented to the positive strand.	Allele T is not associated with resistance to phenytoin in people with Epilepsy as compared to allele C.	T			Is	Not associated with		resistance to		in people with	Other:Epilepsy		C	
1448994156	CYP2C9*1, CYP2C9*3	CYP2C9	phenytoin	14659971	Metabolism/PK	yes	No *3/*3 individuals were observed.	CYP2C9 *1/*3 is associated with increased concentrations of phenytoin in people with Epilepsy as compared to CYP2C9 *1/*1.	*1/*3			Is	Associated with	increased	concentrations of		in people with	Disease:Epilepsy		*1/*1	
1184989363	CYP2C9*1, CYP2C9*3	CYP2C9	phenytoin	25096692	Metabolism/PK	yes	In individuals who experienced severe cutaneous adverse reactions (SCARs) when taking phenytoin, those who carried the CYP2C9*3 allele had significantly higher levels of plasma phenytoin, as compared to those who did not carry the *3 allele.	CYP2C9 *3 is associated with increased concentrations of phenytoin in people with severe cutaneous adverse reactions as compared to CYP2C9 *1/*1.	*3			Is	Associated with	increased	concentrations of		in people with	Disease:severe cutaneous adverse reactions		*1/*1	
981240165	rs1799930	NAT2	isoniazid	19891553	Toxicity, Metabolism/PK	yes	Clearance was also significantly decreased in patients with the GA compared to those with GG, and levels were significantly decreased in patients with AA compared to GA. This is the defining SNP of the NAT2*6 allele.	Genotype AA is associated with decreased clearance of isoniazid in people with Tuberculosis as compared to genotype GG.	AA			Is	Associated with	decreased	clearance of		in people with	Disease:Tuberculosis		GG	
1445388514	CYP2C9*1, CYP2C9*2	CYP2C9	phenytoin	26122019	Metabolism/PK	no	No significant difference in dose-corrected phenytoin concentrations was seen between the *1/*1 and *1/*2 genotypes (p=0.90). Univariate analysis.	CYP2C9 *1/*1 + *1/*2 are not associated with dose-adjusted trough concentrations of phenytoin in people with Epilepsy.	*1/*1 + *1/*2			Are	Not associated with		dose-adjusted trough concentrations of		in people with	Disease:Epilepsy			
1451162800	UGT1A1*1, UGT1A1*28	UGT1A1	raloxifene 6-glucuronide, raloxifene-4′-glucuronide	19371317	Metabolism/PK	yes	M1 is raloxifene 6-glucuronide, M2 is raloxifene-4-glucuronide.	UGT1A1 *28/*28 is associated with increased concentrations of raloxifene 6-glucuronide and raloxifene-4′-glucuronide in women with Osteoporosis as compared to UGT1A1 *1/*1 + *1/*28.	*28/*28			Is	Associated with	increased	concentrations of	and	in women with	Disease:Osteoporosis		*1/*1 + *1/*28	
1451151829	rs6313	HTR2A	risperidone	32462699	Efficacy	yes	Although there was no significant difference between responders and non-responders in terms of overall PANSS score, a significantly increased improvement in negative symptoms was noted across the genotypes GG<AG<AA.	Genotypes AA + AG are associated with increased response to risperidone in people with Schizophrenia as compared to genotype GG.	AA + AG			Are	Associated with	increased	response to		in people with	Other:Schizophrenia		GG	
1451151848	rs6313	HTR2A	olanzapine	32462699	Efficacy	yes	Although there was no significant difference between responders and non-responders in terms of overall PANSS score, a significantly better response in the Emsley's anxiety factor was observed in carriers of the G allele. Please note that alleles have been complemented to the positive strand.	Genotypes AG + GG are associated with increased response to olanzapine in people with Schizophrenia as compared to genotype AA.	AG + GG			Are	Associated with	increased	response to		in people with	Other:Schizophrenia		AA	
1451151860	rs6313	HTR2A	olanzapine	32462699	Efficacy	yes	Although there was no significant difference between responders and non-responders in terms of overall PANSS score, a significantly better response in the Emsley's positive dimension was observed in carriers of the A allele. Please note that alleles have been complemented to the positive strand.	Genotypes AA + AG are associated with increased response to olanzapine in people with Schizophrenia as compared to genotype GG.	AA + AG			Are	Associated with	increased	response to		in people with	Other:Schizophrenia		GG	
1451151940	CYP2D6 poor metabolizer phenotype	CYP2D6	dihydrocodeine	7586928	Metabolism/PK	no	Volunteers were phenotyped using sparteine and debrisoquin. No significant difference in Cmax, AUC terminal half-life or oral clearance between poor metabolizers and normal metabolizers.	CYP2D6 poor metabolizer phenotype is not associated with exposure to dihydrocodeine in healthy individuals as compared to CYP2D6 normal metabolizer phenotype.			poor metabolizer phenotype	Is	Not associated with		exposure to		in healthy individuals				normal metabolizer phenotype
1451151966	CYP2D6 poor metabolizer phenotype	CYP2D6	dihydromorphine	7586928	Metabolism/PK	no	Volunteers were phenotyped using sparteine and debrisoquin. Cmax and AUC of dihydromorphine were significnatly higher in poor metabolizers than in normal metabolizers.	CYP2D6 poor metabolizer phenotype is associated with increased concentrations of dihydromorphine in healthy individuals as compared to CYP2D6 normal metabolizer phenotype.			poor metabolizer phenotype	Is	Associated with	increased	concentrations of		in healthy individuals				normal metabolizer phenotype
1451865260	rs9923231	VKORC1	warfarin	35880564	Dosage	not stated	"as part of dosing algorithm specifically for Honghe Prefecture compared to Han Chinese.  "" The present study found that there was only one case with CYP2C9*1/*2 heterozygous mutation (0.005%) and two patients with VKORC1 GG wild-type homozygous genotype (G>A mutation rate 98%) in Han Chinese. Our studies did not observe these rare genotypes in Honghe minorities."""	Genotype TT is associated with decreased dose of warfarin in people with mechanical heart valve replacement.	TT			Is	Associated with	decreased	dose of		in people with	Other:mechanical heart valve replacement			
1451163180	rs4149056	SLCO1B1	atorvastatin	32128760	Metabolism/PK	yes		Allele C is associated with increased exposure to atorvastatin as compared to allele T.	C			Is	Associated with	increased	exposure to					T	
1451163194	rs887829	UGT1A1, UGT1A10, UGT1A3, UGT1A4, UGT1A5, UGT1A6, UGT1A7, UGT1A8, UGT1A9	atorvastatin	32128760	Metabolism/PK	yes	This variant was associated with increased metabolic ratios of both 2-OH ATV/ATV (P = 7.25 × 10−16) and 2-OH ATV L/ATV L (P = 3.95 × 10−15) at genome-wide significance. This variant is associated with increased hydroxylation of ATV, and not lactonization.	Allele T is associated with increased metabolism of atorvastatin as compared to allele C.	T			Is	Associated with	increased	metabolism of					C	
1451154280	CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*9, CYP2D6*10, CYP2D6*17	CYP2D6	tramadol	12191703	Metabolism/PK	yes	Details about exactly which variants were tested to determine CYP2D6 star alleles are not given.	CYP2D6 *1/*4 + *1/*5 + *1/*9 + *1/*10 + *4/*10 + *5/*10 + *10/*10 + *10/*17 are associated with decreased clearance of tramadol as compared to CYP2D6 *1/*1.	*1/*4 + *1/*5 + *1/*9 + *1/*10 + *4/*10 + *5/*10 + *10/*10 + *10/*17			Are	Associated with	decreased	clearance of					*1/*1	
1446896368	CYP2D6 ultrarapid metabolizer genotype	CYP2D6	tramadol	20488759	Metabolism/PK	yes	"Concentrations of (+)O-demethyltramadol (the active metabolite of tramadol as metabolized by CYP2D6) were significantly elevated in UMs as compared to all other metabolizer statuses. Alleles tested: *3, *4, *5, *6, *7, *8, *10, *41 and gene duplication. Metabolizer status was defined by number of ""functionally active"" alleles: 0=PM; 1=IM; 2=EM; duplication=UM."	CYP2D6 ultrarapid metabolizer genotype is associated with increased metabolism of tramadol.			ultrarapid metabolizer genotype	Is	Associated with	increased	metabolism of						
1451163221	rs45446698	CYP3A7	atorvastatin	32128760	Metabolism/PK	yes	This variant was associated with increased metabolic ratios of 2-OH ATV/ATV (P = 6.18 × 10−7) (increased hydroxylation of ATV) at genome-wide significance.	Allele G is associated with increased metabolism of atorvastatin as compared to allele T.	G			Is	Associated with	increased	metabolism of					T	
1451334662	rs1058164	CYP2D6	aripiprazole	33586456	Metabolism/PK	yes	Authors state that Cmax, t1/2, Tmax and area under the concentration-time curve (AUC0-∞) were all significant although table shows p-values greater than 0.05 for t1/2.	Genotype GG is associated with increased concentrations of aripiprazole in healthy individuals as compared to genotypes CC + CG.	GG			Is	Associated with	increased	concentrations of		in healthy individuals			CC + CG	
1451206740	UGT1A1*1, UGT1A1*28	UGT1A1	irinotecan	18594531	Dosage	no	No significant difference was seen in median total irinotecan dose received over all cycles (g/m2), or in frequency of reductions in irinotecan dose after treatment cycle 1 between the genotypes in patients were treated with irinotecan monotherapy or irinotecan plus capecitabine.	UGT1A1 *1/*28 + *28/*28 are not associated with dose of irinotecan in people with Colorectal Neoplasms as compared to UGT1A1 *1/*1.	*1/*28 + *28/*28			Are	Not associated with		dose of		in people with	Disease:Colorectal Neoplasms		*1/*1	
1451163505	rs4149056	SLCO1B1	rifampin	19374892	Metabolism/PK	no	No significant difference in rifampin AUC between genotype groups. Variant referred to in the paper as c.521T>C.	Allele C is not associated with exposure to rifampin in men as compared to allele T.	C			Is	Not associated with		exposure to		in men			T	
1451334680	rs28371699	CYP2D6	aripiprazole	33586456	Metabolism/PK	yes	Authors state that Cmax, t1/2, Tmax and area under the concentration-time curve (AUC0-∞) were all significant although table shows p-values greater than 0.05 for t1/2.	Genotype AA is associated with increased concentrations of aripiprazole in healthy individuals as compared to genotypes AC + CC.	AA			Is	Associated with	increased	concentrations of		in healthy individuals			AC + CC	
1451334722	CYP2D6 intermediate metabolizer	CYP2D6	aripiprazole	33586456	Metabolism/PK	yes	"Authors state that t1/2 and area under the concentration-time curve (AUC0-∞) were significant but Cmax and Tmax were not.  Authors described as ""extensive metabolizers"" rather than normal metabolizers. There were 54 EMs and 58 IMs (also 28 UMs and no PMs).All subjects were genotyped for CYP2D6*2, *4, *6, *9, *10, *14, *17, *33, *34, *35, *36, *39, *41, *49, *51,; *54, *65, *69.  If subjects had two nonfunctional alleles, a CYP2D6 PM phenotype was assigned;; if subjects harbored one nonfunctional allele and one decreased-function allele or two decreased-function alleles,; a CYP2D6 IM phenotype was assigned; if subjects carried one functional allele, a CYP2D6 EM phenotype was; assigned; if subjects carried more than two functional alleles, a CYP2D6 UM phenotype was assigned."	CYP2D6 intermediate metabolizer is associated with increased concentrations of aripiprazole in healthy individuals as compared to CYP2D6 normal metabolizer.			intermediate metabolizer	Is	Associated with	increased	concentrations of		in healthy individuals				normal metabolizer
1451334781	rs1135840	CYP2D6	aripiprazole	33586456	Metabolism/PK	yes	Authors state that Cmax, t1/2, and area under the concentration-time curve (AUC0-∞) were all significant	Genotype GG is associated with increased concentrations of aripiprazole in healthy individuals as compared to genotypes CC + CG.	GG			Is	Associated with	increased	concentrations of		in healthy individuals			CC + CG	
1451334860	rs28371702	CYP2D6	aripiprazole	33586456	Metabolism/PK	yes	Authors state that Tmax and area under the concentration-time curve (AUC0-∞) were significant	Genotype CC is associated with increased concentrations of aripiprazole in healthy individuals as compared to genotypes AA + AC.	CC			Is	Associated with	increased	concentrations of		in healthy individuals			AA + AC	
1448099915	CYP2D6 normal metabolizer genotype	CYP2D6	flecainide	26195225	Metabolism/PK	yes	This is a study of the effect of CYP2D6 variation on the ratio of S- to R-flecainide measured at trough concentrations. Patients received flecainide for at least 2 months before blood withdrawal. A; lower serum flecainide S/R ratio corresponded to impaired CYP2D6 activity derived from the CYP2D6 IMs/PMs genotype or coadministration of the potent CYP2D6 inhibitor.	CYP2D6 normal metabolizer genotype is associated with concentrations of flecainide in people with Tachycardia, Supraventricular as compared to CYP2D6 poor metabolizer and intermediate metabolizer genotypes.			normal metabolizer genotype	Is	Associated with		concentrations of		in people with	Disease:Tachycardia, Supraventricular			poor metabolizer and intermediate metabolizer genotypes
1451317740	CYP2C9 poor metabolizers	CYP2C9	olanzapine	33378980	Metabolism/PK	yes	CYP2C9 PMs had a significantly increased half-life and Vd/F of olanzapine as compared to CYP2C9 NMs and IMs. The authors identified the CYP2C9*2 and *3 alleles using the SNPs rs1799853 and rs1057910, respectively. Subjects were grouped into phenotype groups using CPIC assignments.	CYP2C9 poor metabolizers are associated with increased exposure to olanzapine in healthy individuals as compared to CYP2C9 intermediate metabolizer and normal metabolizer.			poor metabolizers	Are	Associated with	increased	exposure to		in healthy individuals				intermediate metabolizer and normal metabolizer
1451335308	rs2273697	ABCC2	olanzapine	33378980	Metabolism/PK	no	No significant difference in a number of pharmacokinetic parameters was found between genotypes.	Allele A is not associated with exposure to olanzapine in healthy individuals as compared to allele G.	A			Is	Not associated with		exposure to		in healthy individuals			G	
1451866750	rs3742879	ARG2	Methyldopa	35971863	Efficacy	yes	"""The novel findings were that the G allele for ARG2 SNP rs3742879 (A>G) was less frequent in nonresponsive PE patients and individuals in this nonresponsive subgroup carrying the G allele (AG + GG) had lower plasma levels of arginase 2 and higher concentrations of nitrite compared with individuals carrying the AA genotype. """	Allele G is associated with increased response to Methyldopa in women with Pregnancy and Pre-Eclampsia as compared to allele A.	G			Is	Associated with	increased	response to		in women with	Other:Pregnancy, Other:Pre-Eclampsia	and	A	
1451206861	rs1128503	ABCB1	morphine	24747667	Metabolism/PK	yes	Post-mortem analysis of codeine-related deaths. Cases with the AG or GG genotypes had significantly lower concentrations of morphine produced from codeine metabolism than AA cases. Please note that alleles have been complemented to the positive strand.	Genotypes AG + GG are associated with decreased concentrations of morphine as compared to genotype AA.	AG + GG			Are	Associated with	decreased	concentrations of					AA	
1451206834	rs2032582	ABCB1	codeine, morphine	24747667	Metabolism/PK	no	Post-mortem analysis of codeine-related deaths. No significant association between this variant and concentrations of codeine or morphine resulting from codeine metabolism. Please note that alleles have been complemented to the positive strand.	Allele T is not associated with concentrations of codeine or morphine as compared to allele C.	T			Is	Not associated with		concentrations of	or				C	
1451335158	rs1045642	ABCB1	olanzapine	33378980	Metabolism/PK	no	No significant difference in a number of pharmacokinetic parameters was found between genotypes. Please note that alleles have been complemented to the positive strand.	Allele G is not associated with exposure to olanzapine in healthy individuals as compared to allele A.	G			Is	Not associated with		exposure to		in healthy individuals			A	
1451866940	rs1045642	ABCB1	atorvastatin	35968761	Efficacy	yes	"as measured by reduction in total cholesterol and LDL. ""Effective reduction of TCL and LDL-C was observed in the TT genotype of ABCB1 (rs1045642) as compared with the CC + CT genotype. "" Alleles complemented to plus chromosomal strand."	Genotype AA is associated with increased clinical benefit to atorvastatin in people with Coronary Artery Disease as compared to genotypes AG + GG.	AA			Is	Associated with	increased	clinical benefit to		in people with	Other:Coronary Artery Disease		AG + GG	
1451206853	rs1799971	OPRM1	codeine, morphine	24747667	Metabolism/PK	no	Post-mortem analysis of codeine-related deaths. No significant association between this variant and concentrations of codeine or morphine resulting from codeine metabolism.	Allele G is not associated with concentrations of codeine or morphine as compared to allele A.	G			Is	Not associated with		concentrations of	or				A	
1451335303	rs7787082	ABCB1	olanzapine	33378980	Metabolism/PK	no	No significant difference in a number of pharmacokinetic parameters was found between genotypes. Please note that alleles have been complemented to the positive strand.	Allele A is not associated with exposure to olanzapine in healthy individuals as compared to allele G.	A			Is	Not associated with		exposure to		in healthy individuals			G	
1451335460	rs2108622	CYP4F2	olanzapine	33378980	Metabolism/PK	no	No significant difference in a number of pharmacokinetic parameters was found between genotypes.	Allele T is not associated with exposure to olanzapine in healthy individuals as compared to allele C.	T			Is	Not associated with		exposure to		in healthy individuals			C	
1451335452	rs6314	HTR2A	olanzapine	33378980	Metabolism/PK	no	No significant difference in a number of pharmacokinetic parameters was found between genotypes.	Genotype AG is not associated with exposure to olanzapine in healthy individuals as compared to genotype GG.	AG			Is	Not associated with		exposure to		in healthy individuals			GG	
1451335520	rs7997012	HTR2A	olanzapine	33378980	Metabolism/PK	no	No significant difference in a number of pharmacokinetic parameters was found between genotypes.	Allele G is not associated with exposure to olanzapine in healthy individuals as compared to allele A.	G			Is	Not associated with		exposure to		in healthy individuals			A	
1451866947	rs2306283	SLCO1B1	atorvastatin	35968761	Efficacy	yes	"as measured by reduction in total cholesterol. ""SLCO1B1 c.388 A>G (rs2306283) showed a significant reduction in TG (p = 0.033) levels with a maximal reduction in wild-type AA (-29.2 ± 31.6) as compared with AG + GG (-11.9 ± 35.2) genotypes"""	Genotype AA is associated with increased clinical benefit to atorvastatin in people with Coronary Artery Disease as compared to genotypes AG + GG.	AA			Is	Associated with	increased	clinical benefit to		in people with	Other:Coronary Artery Disease		AG + GG	
1451206886	rs1045642	ABCB1	codeine, morphine	24747667	Metabolism/PK	no	Post-mortem analysis of codeine-related deaths. No significant association between this variant and concentrations of codeine or morphine resulting from codeine metabolism. Please note that alleles have been complemented to the positive strand.	Allele A is not associated with concentrations of codeine or morphine as compared to allele G.	A			Is	Not associated with		concentrations of	or				G	
1451335447	rs6277	DRD2	olanzapine	33378980	Metabolism/PK	no	No significant difference in a number of pharmacokinetic parameters was found between genotypes.	Allele A is not associated with exposure to olanzapine in healthy individuals as compared to allele G.	A			Is	Not associated with		exposure to		in healthy individuals			G	
1451335416	rs1800497	ANKK1, DRD2	olanzapine	33378980	Metabolism/PK	no	No significant difference in a number of pharmacokinetic parameters was found between genotypes. This variant is referred to in the paper as the Taq1A variant.	Allele A is not associated with exposure to olanzapine in healthy individuals as compared to allele G.	A			Is	Not associated with		exposure to		in healthy individuals			G	
1451335433	rs6280	DRD3	olanzapine	33378980	Metabolism/PK	no	No significant difference in a number of pharmacokinetic parameters was found between genotypes.	Allele T is not associated with exposure to olanzapine in healthy individuals as compared to allele C.	T			Is	Not associated with		exposure to		in healthy individuals			C	
1451335582	rs1137101	LEPR	olanzapine	33378980	Metabolism/PK	no	No significant difference in a number of pharmacokinetic parameters was found between genotypes.	Allele G is not associated with exposure to olanzapine in healthy individuals as compared to allele A.	G			Is	Not associated with		exposure to		in healthy individuals			A	
1451164240	UGT1A1*1, UGT1A1*28	UGT1A1	atazanavir	17148966	Metabolism/PK	no	No significant difference in minimum concentrations of atazanavir were found between the (TA)7/(TA)7, (TA)6/(TA)7 and (TA)6/(TA)6 genotypes.	UGT1A1 *28 is not associated with concentrations of atazanavir in people with HIV Infections as compared to UGT1A1 *1.	*28			Is	Not associated with		concentrations of		in people with	Other:HIV Infections		*1	
1451317820	rs34059508	SLC22A1	olanzapine	33378980	Metabolism/PK	yes	The A allele is referred to in the paper as SLC22A1*5. Participants with the *1/*5 genotype had a significantly increased AUC and Cmax compared to *1/*1.	Genotype AG is associated with increased exposure to olanzapine in healthy individuals as compared to genotype GG.	AG			Is	Associated with	increased	exposure to		in healthy individuals			GG	
1451317900	rs5128	APOC3	olanzapine	33378980	Metabolism/PK	no	There was a trend for CG individuals to have an increased Vd/F compared to GG individuals.	Genotype CG is associated with increased exposure to olanzapine in healthy individuals as compared to genotype GG.	CG			Is	Associated with	increased	exposure to		in healthy individuals			GG	
1451155580	CYP2D6 poor metabolizer	CYP2D6	tramadol	15906019	PD	not stated	PMs showed no change in pupil diameter in static pupillometry, while NMs showed a decrease in pupil diameter. A tramadol-induced effect on pupil diameter was seen in PMs using dynamic pupillometry, but the duration of this effect was shorter than in NMs. Half of the cohort had their metabolizer status assigned by phenotyping with sparteine, while the other half were genotyped (details of genotyping assay not provided).	CYP2D6 poor metabolizer is associated with decreased response to tramadol in healthy individuals as compared to CYP2D6 normal metabolizer.			poor metabolizer	Is	Associated with	decreased	response to		in healthy individuals				normal metabolizer
1451341440	rs1042713	ADRB2	salmeterol	30425908	Efficacy	yes	The presence of the G allele in the ADRB2 variant +46A>G correlates with better bronchodilator response to salbutamol.	Allele G is associated with increased response to salmeterol in children Asthma as compared to allele A.	G	Pediatric		Is	Associated with	increased	response to		in children	Other:Asthma		A	
1451317880	rs3842	ABCB1	olanzapine	33378980	Metabolism/PK	yes		Allele T is associated with increased clearance of olanzapine in healthy individuals as compared to allele C.	T			Is	Associated with	increased	clearance of		in healthy individuals			C	
1451155685	CYP2D6 poor metabolizer phenotype	CYP2D6	tramadol	16129989	Efficacy	yes	Patients treated with tramadol had significantly lower pain intensity scores in the first week of treatment. However, this difference was not found at any other timepoint. Patients were phenotyped using dextromethorphan.	CYP2D6 poor metabolizer phenotype is associated with increased response to tramadol in people with Phantom limb syndrome as compared to CYP2D6 normal metabolizer phenotype.			poor metabolizer phenotype	Is	Associated with	increased	response to		in people with	Other:Phantom limb syndrome			normal metabolizer phenotype
1451155780	CYP2D6*1, CYP2D6*4, CYP2D6*6	CYP2D6	tramadol	16763825	Metabolism/PK	yes	Individuals with the *4/*4 or *4/*6 genotypes had significantly increased AUCs and half-lives of (+)- and (-)-tramadol and significantly lower AUCs and half-lives of (+)- and (-)-M1. compared to *1/*1 individuals. Subjects were phenotyped using sparteine and tramadol as well as genotyped for the *3, *4, *6 and *9 alleles.	CYP2D6 *4/*4 + *4/*6 are associated with decreased metabolism of tramadol in healthy individuals as compared to CYP2D6 *1/*1.	*4/*4 + *4/*6			Are	Associated with	decreased	metabolism of		in healthy individuals			*1/*1	
1451341447	rs1042714	ADRB2	salmeterol	30425908	Efficacy	no	No significant association of +79C>G polymorphisms with the asthma severity and bronchodilator response to inhaled salbutamol was found.	Allele G is not associated with increased response to salmeterol in children Asthma as compared to allele C.	G	Pediatric		Is	Not associated with	increased	response to		in children	Other:Asthma		C	
1451164700	rs4149056	SLCO1B1	rosuvastatin	31857620	Efficacy	no	SLCO1B1 521T > C IS partially associated with a higher AUC of rosuvastatin in young subjects and a less pronounced increasing trend in elderly subjects (p > 0.05 for both).	Genotypes CC + CT are associated with response to rosuvastatin as compared to genotype TT.	CC + CT			Are	Associated with		response to					TT	
1451207688	UGT1A1*1, UGT1A1*28	UGT1A1	irinotecan	18300238	Dosage	yes	Carriers of the (TA)7 allele had an increased incidence of irinotecan dose reductions compared to those homozygous for the (TA)6 allele. Patients were given irinotecan in combination with 5-fluorouracil and leucovorin (FOLFIRI), administered every 2 weeks for 12 cycles.	UGT1A1 *1/*28 + *28/*28 are associated with decreased dose of irinotecan in people with Colorectal Neoplasms as compared to UGT1A1 *1/*1.	*1/*28 + *28/*28			Are	Associated with	decreased	dose of		in people with	Disease:Colorectal Neoplasms		*1/*1	
1451155820	CYP2D6 poor metabolizer phenotype	CYP2D6	tramadol	17175164	Metabolism/PK	yes	Poor metabolizers had significantly higher AUCs of (+)- and (-)- tramadol and significantly reduced clearance of tramadol compared to normal metabolizers. Subjects were phenotyped using tramadol.	CYP2D6 poor metabolizer phenotype is associated with decreased metabolism of tramadol in healthy individuals as compared to CYP2D6 normal metabolizer phenotype.			poor metabolizer phenotype	Is	Associated with	decreased	metabolism of		in healthy individuals				normal metabolizer phenotype
1451164800	rs2231142	ABCG2	rosuvastatin	31857620	Efficacy	no	ABCG2 421C>A did not significantly affect the lipid-lowering response of rosuvastatin.	Genotypes GT + TT are not associated with response to rosuvastatin as compared to genotype GG.	GT + TT			Are	Not associated with		response to					GG	
1451207760	CYP2D6 poor metabolizers	CYP2D6	dabigatran	32564268	Metabolism/PK	yes	As compared to intermediate, normal and ultrarapid metabolizers combined. Patients were genotyped for the following variants: CYP2D6*3 (rs35742686), *4 (rs3892097), *6 (rs5030655), *7 (rs5030867), *8 (rs5030865), *9 (rs5030656), *10 (rs1065852), *14 (rs5030865), *17 (rs28371706), *41 (rs28371725) and CNVs. Detected genotypes are not presented in the paper.	CYP2D6 poor metabolizers are associated with decreased clearance of Dabigatran in healthy individuals.			poor metabolizers	Are	Associated with	decreased	clearance of		in healthy individuals				
1451156320	CYP2D6 poor metabolizer genotype	CYP2D6	methadone	17234366	Efficacy	no	No significant difference in patient satisfaction with methadone maintenance therapy between normal and poor metabolizers. Paper states that the *1, *2, *3, *4, *5, *6, *9, *10, *1x2 and *2x2 alleles were found in the patient cohort but does not provide information about which genotypes were found or which specific variants were tested for in the assay.	CYP2D6 poor metabolizer genotype is not associated with response to methadone in people with Heroin Dependence as compared to CYP2D6 normal metabolizer genotype.			poor metabolizer genotype	Is	Not associated with		response to		in people with	Other:Heroin Dependence			normal metabolizer genotype
1449310660	rs1057910	CYP2C9	sulfonamides, urea derivatives	29681852	Efficacy	no	This is the defining SNP of CYP2C9*3	Allele C is not associated with response to sulfonamides, urea derivatives in people with Diabetes Mellitus as compared to allele A.	C			Is	Not associated with		response to		in people with	Disease:Diabetes Mellitus		A	
1451164966	rs2306283	SLCO1B1	atorvastatin	31594719	Metabolism/PK	no		Genotypes AA + AG are not associated with increased concentrations of atorvastatin in people with Hypercholesterolemia as compared to genotype GG.	AA + AG			Are	Not associated with	increased	concentrations of		in people with	Other:Hypercholesterolemia		GG	
